Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.
about
Anti-fibro-hepatocarcinogenic Chinese herbal medicines: A mechanistic overviewPharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveAdvances in the treatment of invasive neonatal candidiasisVoriconazole pharmacokinetics and pharmacodynamics in children.Voriconazole pharmacokinetics in liver transplant recipients.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisVoriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyEvaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infectionsPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channelsUPLC-MS/MS determination of voriconazole in human plasma and its application to a pharmacokinetic study.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Multiple Scedosporium apiospermum abscesses in a woman survivor of a tsunami in northeastern Japan: a case report.Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicityTrough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.A rapid MCM-41 dispersive micro-solid phase extraction coupled with LC/MS/MS for quantification of ketoconazole and voriconazole in biological fluids.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazolePharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.In search of the holy grail of antifungal therapyVoriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.Software for dosage individualization of voriconazole for immunocompromised patientsPractice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Current options in antifungal pharmacotherapy.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Antifungal agents--clinical pharmacokinetics and drug interactions.Antifungal therapeutic drug monitoring: established and emerging indications.Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.Tissue penetration of antifungal agents.Voriconazole therapeutic drug monitoring: focus on safety.
P2860
Q26745650-6F53ACC3-14B2-4683-A1FD-8F0B1FDDC48CQ26771180-223D9F48-DCC3-4371-84CA-04D4D7CB1EFCQ27009221-DF5107AF-91D4-4A2C-BBB6-CE14EC5A5089Q27022585-2FDF1F4B-3207-40EF-830B-735748387762Q33577291-A3703DFD-39F0-498D-88C7-42CABD017F34Q33613685-D8C570C1-B748-4AE8-AF6E-97952A8A8B3DQ33849298-6E655658-9F5B-47C4-9899-82C6A7AF32B8Q34020402-C8608B51-9A0D-4CC5-9EE2-796AA42FDDACQ34045383-BA2AF60B-5205-4601-8DCE-3F9F663886F3Q34150923-C5D4443A-91F9-4CD9-9811-587AB5833E94Q34150943-4E51D96B-4FE2-4A3F-BBCA-B7354C4C43DBQ34413393-A238D856-4C7F-4EE7-B3B8-1795FD81B85BQ34483712-D15646C0-F5FC-4A2E-BA87-D487D1919D2DQ34532546-99964F32-A959-4D60-BF35-22F21FACEF36Q35026481-646F39E4-A3CB-4E66-B164-63EE21CC90D3Q35121384-312B77FE-5DFF-4663-BDD9-93A1C48B411FQ35187285-DFB51B50-A70E-4EA7-959A-A371FD5529CAQ35270270-7E44238A-CACC-4845-8573-26F685CAE43DQ35364006-3DB1D667-8E48-4728-8C1B-694327BBAAA9Q35571541-13B33A5E-BDD1-40B1-928D-33B3BD4E14C2Q35889014-3024F18B-7DCC-418A-A8F8-8EA9DDF4A5B0Q35941502-C13D40B6-84E3-48D2-9F16-406F75B21410Q35954530-BF804378-8080-46D5-BA47-784870389B39Q36090668-C8D057F2-67CE-443C-98D1-AC947ECBAE74Q36172497-7FF3A087-BADE-4FDF-995C-0F581843071BQ36521993-5A67DB91-7FD0-4D5C-8CA3-79DDA31519AFQ36536413-655D278C-9B00-450E-9411-FDCEC70816CFQ36608562-4FC465D9-E5E8-4D7C-BB1F-96A39F9687F0Q36672181-FB7390B7-4862-4416-B0AA-F57CA875F6BCQ36696390-58ED3FED-F6FF-4933-A117-6D7560A0A8D0Q36730105-B3F479A4-D61F-4CA5-8B83-2FEB57B04E42Q36757595-BC757AD3-5C56-4DFA-A224-550249A09505Q36927577-9539199B-7F31-4F4B-8D0C-5BA5EB3A70C4Q37151326-BEA8183A-0CE4-4164-B833-693C96EFCE21Q37157893-8C96CEAD-731F-49E4-B06E-6C68106CCCAEQ37159568-D7748107-A629-4456-9A59-172F9581FF4AQ37310029-8269A760-2F3F-43B1-923C-58AB5A659DFDQ37328834-C5D126BA-0E12-4530-A95A-D138490A7794Q37544911-0C9F41A8-4272-41B1-9938-C2F71DB487B5Q37658869-FCBB03DC-DA5E-4A91-96E0-FCAED5323225
P2860
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Investigation of the potential ...... r function test abnormalities.
@en
Investigation of the potential ...... r function test abnormalities.
@nl
type
label
Investigation of the potential ...... r function test abnormalities.
@en
Investigation of the potential ...... r function test abnormalities.
@nl
prefLabel
Investigation of the potential ...... r function test abnormalities.
@en
Investigation of the potential ...... r function test abnormalities.
@nl
P2093
P2860
P356
P1476
Investigation of the potential ...... r function test abnormalities.
@en
P2093
Konrad Tomaszewski
Nigel Brayshaw
Nolan Wood
Peter Troke
P2860
P304
P356
10.1177/0091270005283837
P577
2006-02-01T00:00:00Z